Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-EC-G
- Development stage
- Preclinical
- Lead developer
- Cell>Point LLC
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-EC-G is a gallium-68 labeled radiopharmaceutical developed by Cell>Point. It utilizes Cell>Point's Ethylenedicysteine-Glucosamine (EC-G) technology platform and is intended for Positron Emission Tomography (PET) imaging in both cancer and cardiology. The glucosamine component likely facilitates targeting of cells with altered glucose metabolism, a common characteristic in many cancers and relevant for assessing myocardial viability in cardiology.
- Other names
- Gallium-68 Ethylenedicysteine-GlucosamineGallium68 Ethylenedicysteine-GlucosamineGallium 68 Ethylenedicysteine-Glucosamine
Beyond the preview
Go deeper on 68Ga-EC-G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-EC-G.